Skip to content

Assessment Tool for Older Patients With Cancer

Determining the Utility of an Assessment Tool for Older Patients With Cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00477958
Enrollment
1062
Registered
2007-05-24
Start date
2006-12-19
Completion date
2027-02-17
Last updated
2026-03-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cognitive/Functional Effects, Psychosocial Effects of Cancer and Its Treatment, Unspecified Adult Solid Tumor, Protocol Specific

Keywords

cognitive/functional effects, psychosocial effects of cancer and its treatment, unspecified adult solid tumor, protocol specific

Brief summary

RATIONALE: A study that assesses the ability of older patients to think, learn, remember, make judgments, and carry out daily activities may help doctors plan treatment for older patients with cancer. PURPOSE: This clinical trial is studying an assessment tool in older patients with cancer.

Detailed description

OBJECTIVES: Primary * Determine whether a geriatric assessment tool can predict toxicity to chemotherapy, defined as grade 3 or 4 toxicity, hospitalization, dose delay or reduction, or discontinuation of chemotherapy due to toxicity, in elderly patients with cancer. Secondary * Explore the longitudinal impact of cancer and chemotherapy treatment on geriatric assessment parameters. OUTLINE: Patients undergo assessments of functional status using the Timed Up and Go Assessment (measures physical mobility) and Karnofsky Physician-Rated Performance Rating Scale; and cognition using the Blessed Orientation-Memory-Concentration Test. These assessments are performed by healthcare personnel. Body mass index and the percentage of unintentional weight loss and the number of falls in the past 6 months are also assessed. Patients also complete the following self-administered questionnaires: Instrumental Activities of Daily Living (measures level of functioning and need for services); Activities of Daily Living (measures higher levels of physical functioning); Karnofsky Self-Reported Performance Rating Scale (related to survival and clinically significant illness); Physical Health Section of the Older American Resources and Services Questionnaire (measures comorbidity and the impact on daily activities); Hospital Anxiety and Depression Scale; Medical Outcomes Study (MOS) Social Activity Limitations Measure (measures the impact of cancer on patients' social functioning); and MOS Social Support Survey Emotional/Information and Tangible Subscales (measures perceived availability of social support). Patients then begin planned chemotherapy. After completion of chemotherapy (or a maximum of 12 months from study entry), patients undergo assessments and complete self-administered questionnaires as described above. PROJECTED ACCRUAL: A total of 750 patients will be accrued for this study.

Interventions

OTHERquestionnaire administration

Questionnaire administered prior to chemotherapy and within 30 days of completion of chemotherapy.

PROCEDUREcognitive assessment

Cognitive assessment to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.

PROCEDUREpsychosocial assessment and care

Psychosocial assessment and care to be obtained prior to chemotherapy and within 30 days of completion of chemotherapy.

Sponsors

City of Hope Medical Center
Lead SponsorOTHER
National Cancer Institute (NCI)
CollaboratorNIH

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
65 Years to 120 Years
Healthy volunteers
No

Inclusion criteria

DISEASE CHARACTERISTICS: * Pathologically confirmed cancer * Receiving chemotherapy for either adjuvant treatment or metastatic disease prior to beginning a new chemotherapy regimen PATIENT CHARACTERISTICS: * Must be able to understand English PRIOR CONCURRENT THERAPY: * See Disease Characteristics * No prior enrollment in this trial * No concurrent enrollment on a phase I clinical trial

Design outcomes

Primary

MeasureTime frame
Ability to predict toxicity to chemotherapy, defined as grade 3-4 toxicity, hospitalization, dose delay or reduction, or discontinuation of chemotherapy due to toxicity, as measured by a geriatric assessment toolPrior to chemotherapy and within 30 days of completion of chemotherapy.

Secondary

MeasureTime frame
Longitudinal impact of cancer and chemotherapy treatment on geriatric assessment parametersPrior to chemotherapy and within 30 days of completion of chemotherapy.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATORDale William, MD

City of Hope Medical Center

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 28, 2026